AU
UK
CA
US
IND
NZ
Last update at 2026-06-11T15:33:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Thu 08 May 25, 11:00 AMWerewolf Therapeutics to Participate in Upcoming Investor Conferences
Mon 05 May 25, 12:00 PMWerewolf Therapeutics Appoints Steven Bloom as Chief Business Officer
Thu 17 Apr 25, 12:00 PMWerewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors
Mon 24 Feb 25, 12:30 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Income before tax | -53.81000M | -49.98300M | -15.04000M | -10.24800M |
| Minority interest | - | - | - | - |
| Net income | -51.56400M | -49.76700M | -14.93900M | -10.99000M |
| Selling general administrative | 18.70M | 14.82M | 5.76M | 3.60M |
| Selling and marketing expenses | - | - | - | - |
| Gross profit | 16.40M | - | - | - |
| Reconciled depreciation | 1.10M | 0.22M | 0.15M | 0.03M |
| Ebit | -57.16000M | -50.30300M | -22.40400M | -9.93600M |
| Ebitda | -56.05600M | -50.08700M | -22.25400M | -9.54100M |
| Depreciation and amortization | 1.10M | 0.22M | 0.15M | 0.40M |
| Non operating income net other | 2.25M | 0.10M | - | - |
| Operating income | -56.05600M | -50.08700M | -22.40400M | -9.93600M |
| Other operating expenses | 72.46M | 50.09M | 22.40M | 9.94M |
| Interest expense | 1.10M | 0.22M | 0.10M | 0.00000M |
| Tax provision | - | - | - | - |
| Interest income | 1.91M | 0.10M | - | - |
| Net interest income | 1.91M | 0.10M | 0.10M | -0.37200M |
| Extraordinary items | - | - | - | - |
| Non recurring | - | - | - | - |
| Other items | - | - | - | - |
| Income tax expense | -2.24600M | -0.21600M | -0.10100M | 0.74M |
| Total revenue | 16.40M | 0.00000M | 0.00000M | 0.00000M |
| Total operating expenses | 72.46M | 50.09M | 22.40M | 9.94M |
| Cost of revenue | - | - | - | - |
| Total other income expense net | 2.25M | 0.10M | 7.36M | -0.31200M |
| Discontinued operations | - | - | - | - |
| Net income from continuing ops | -53.81000M | -49.98300M | -15.04000M | -10.24800M |
| Net income applicable to common shares | -53.81000M | 101.96M | -28.21700M | -18.22900M |
| Preferred stock and other adjustments | - | 151.94M | - | - |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 126.93M | 174.83M | 160.25M | 179.25M | 96.40M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 2.07M | 2.68M | 3.96M | 3.54M | 0.34M |
| Total liab | 53.54M | 63.46M | 37.91M | 26.46M | 148.26M |
| Total stockholder equity | 73.39M | 111.37M | 122.34M | 152.79M | -51.86300M |
| Deferred long term liab | - | - | - | - | 0.15M |
| Other current liab | 10.59M | 8.86M | 14.15M | 8.77M | 3.59M |
| Common stock | 0.00500M | 0.00400M | 0.00300M | 0.00200M | 0.00200M |
| Capital stock | 0.00500M | 0.00400M | 0.00300M | 0.00200M | 0.00200M |
| Retained earnings | -414.58800M | -344.07300M | -306.70500M | -252.89500M | -51.86500M |
| Other liab | - | - | - | - | 0.03M |
| Good will | - | - | - | - | - |
| Other assets | - | 0.00000M | 10.88M | 1.86M | 0.36M |
| Cash | 111.00M | 134.34M | 129.31M | 157.53M | 92.57M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 15.18M | 19.38M | 23.99M | 11.87M | 5.28M |
| Current deferred revenue | - | 0.91M | 6.53M | - | - |
| Net debt | -73.90800M | -82.42000M | -114.63100M | -141.87000M | -90.02900M |
| Short term debt | 1.56M | 8.28M | 2.08M | 1.07M | 0.68M |
| Short long term debt | - | 6.67M | - | - | - |
| Short long term debt total | 37.09M | 51.92M | 14.68M | 15.66M | 2.54M |
| Other stockholder equity | 487.97M | 455.44M | 429.04M | 405.68M | 0.17M |
| Property plant equipment | - | - | 8.99M | 16.32M | 3.12M |
| Total current assets | 113.07M | 138.37M | 140.20M | 161.07M | 92.91M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | 122.34M | 152.79M | -51.86300M |
| Short term investments | - | - | - | - | - |
| Net receivables | - | 1.35M | 6.93M | - | - |
| Long term debt | 26.09M | 32.66M | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts payable | 3.04M | 1.34M | 1.22M | 2.04M | 1.02M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | -179.25000M | -0.17500M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 0.00300M | 0.00200M | 0.00200M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | -306.70500M | -252.89500M | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 1.54M | 0.59M | 2.59M | 1.86M | 0.36M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 13.86M | 36.46M | 20.05M | 18.18M | 3.48M |
| Capital lease obligations | 10.99M | 12.60M | 14.68M | 15.66M | 2.54M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | -3.61100M | -0.49800M | -0.56000M | -0.26600M |
| Change to liabilities | 3.05M | 1.01M | 0.39M | 0.12M |
| Total cashflows from investing activities | -3.61100M | -0.49800M | -0.56000M | -0.26600M |
| Net borrowings | -0.08800M | - | - | - |
| Total cash from financing activities | 15.91M | 109.43M | 93.86M | 21.91M |
| Change to operating activities | - | 1.27M | 1.92M | -0.82700M |
| Net income | -53.81000M | -49.98300M | -15.04000M | -10.24800M |
| Change in cash | -28.30100M | 66.05M | 74.67M | 12.10M |
| Begin period cash flow | 158.83M | 92.78M | 18.10M | 6.00M |
| End period cash flow | 130.53M | 158.83M | 92.78M | 18.10M |
| Total cash from operating activities | -40.59600M | -42.87600M | -18.62400M | -9.54200M |
| Issuance of capital stock | 16.19M | 111.60M | 94.17M | 22.10M |
| Depreciation | 1.10M | 0.22M | 0.15M | 0.03M |
| Other cashflows from investing activities | - | - | - | - |
| Dividends paid | - | - | - | - |
| Change to inventory | - | - | - | - |
| Change to account receivables | - | - | - | - |
| Sale purchase of stock | 15.99M | 109.43M | - | - |
| Other cashflows from financing activities | -0.28500M | -2.17300M | 93.86M | 21.91M |
| Change to netincome | 7.41M | 4.61M | -6.04200M | 1.39M |
| Capital expenditures | 3.61M | 0.50M | 0.56M | 0.27M |
| Change receivables | -6.92800M | - | - | - |
| Cash flows other operating | 8.38M | -3.44300M | - | - |
| Exchange rate changes | - | - | - | - |
| Cash and cash equivalents changes | -28.30100M | 66.05M | - | - |
| Change in working capital | 2.54M | 2.28M | 2.31M | -0.71100M |
| Stock based compensation | 7.40M | 4.09M | 0.63M | 0.56M |
| Other non cash items | 2.17M | 0.52M | 0.63M | 0.95M |
| Free cash flow | -44.20700M | -43.37400M | -19.18400M | -9.80800M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| HOWL Werewolf Therapeutics Inc |
0.0063 1.73% | 0.37 | - | - | 43.58 | 0.87 | 0.67 | 0.57 |
| NVO Novo Nordisk A/S |
0.65 1.51% | 43.45 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-0.0438 0.10% | 43.30 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
3.47 0.80% | 439.18 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
11.33 1.88% | 612.98 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. The company's lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
200 Talcott Ave, Watertown, MA, United States, 02472
| Name | Title | Year Born |
|---|---|---|
| Dr. Daniel J. Hicklin Ph.D. | Founder, CEO, Pres, Sec. & Director | 1964 |
| Mr. Timothy W. Trost CPA | CFO, Treasurer & Assistant Sec. | 1958 |
| Dr. Chulani Karunatilake Ph.D. | Chief Technology Officer | NA |
| Dr. Reid Leonard Ph.D. | Chief Operating Officer | 1959 |
| Dr. Cynthia Seidel-Dugan Ph.D. | Chief Scientific Officer | 1959 |
| Dr. Randi Isaacs M.D. | Chief Medical Officer | 1956 |
| Ms. Ellen A. Lubman M.B.A. | Chief Bus. Officer | 1976 |
| Dr. Daniel J. Hicklin Ph.D. | Founder, CEO, President, Secretary & Director | 1964 |
| Mr. Timothy W. Trost CPA | CFO, Treasurer & Assistant Secretary | 1958 |
| Dr. Chulani Karunatilake Ph.D. | Chief Technology Officer | 1959 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...